The At its meeting in December 2022, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a Recommendation for approval for Etranacogen dezaparvovec (Hemgenix, CSLBehring) given:
Gene therapy should be used for severe and moderate haemophilia B (congenital factor IX deficiency) in adult patients without a history of factor IX inhibitors.
This full text is unfortunately reserved for medical professionals
You have reached the maximum number of articles for unregistered visitors
Source — https://www.univadis.de/viewarticle/ema-empfiehlt-zulassung-f%25C3%25BCr-etranacogen-dezaparvovec-2022a10028o5
Comments are closed.